Medullary thyroid carcinoma and multiple endocrine neoplasia type 2.

scientific article

Medullary thyroid carcinoma and multiple endocrine neoplasia type 2. is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1022721494
P356DOI10.1385/EP:14:2:123
P698PubMed publication ID12858002

P2093author name stringHiroshi Takami
P2860cites workAlternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide productsQ28264638
Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processingQ28266416
Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and hirschsprung diseaseQ28305753
Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2BQ28776010
Importance of early screening and prophylactic thyroidectomy in asymptomatic nonindex RET germline carriersQ30320962
Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical propertiesQ30321003
Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience.Q30321277
Normal thyroid pathology in patients undergoing thyroidectomy for finding a RETgene germline mutation: a report of three cases and review of the literatureQ33544569
Guidelines for diagnosis and therapy of MEN type 1 and type 2.Q34104591
Multiple endocrine neoplasia type 2: molecular aspectsQ34302453
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.Q34334980
Advances in the diagnosis and treatment of medullary thyroid carcinoma.Q39462141
C-cell disease of the thyroid gland in multiple endocrine neoplasia, type 2BQ39824843
Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs a Calcitonine (GETC).Q40776760
The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysisQ40920116
Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systemsQ41722801
Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinomaQ42461766
Improved prediction of calcitonin normalization in medullary thyroid carcinoma patients by quantitative lymph node analysisQ42486469
Improved diagnostic methods in the follow-up of medullary thyroid carcinoma by highly specific calcitonin measurementsQ42488900
Calcitonin gene-related peptide in patients with endocrine tumorsQ43617448
V804M RET mutation and familial medullary thyroid carcinoma: report of a large family with expression of the disease only in the homozygous gene carriersQ43999293
Mutational analysis of the RET proto-oncogene in 71 Japanese patients with medullary thyroid carcinomaQ47989213
Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.Q48114164
Partial nucleotide sequence of human calcitonin precursor mRNA identifies flanking cryptic peptidesQ48406076
Medullary thyroid carcinoma: clinical features and long-term follow-up of seventy-eight patients treated between 1969 and 1986.Q50875910
Medullary carcinoma of the thyroid: prognostic factors and treatment recommendations.Q50899149
Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables.Q51035989
PDN-21: possible tumor marker for medullary thyroid carcinoma.Q53801229
Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. Groupe D'etude des Tumeurs à Calcitonine.Q54435233
A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinomaQ55670928
Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTCQ57591365
Calcitonin gene-related peptide as a tumor marker for medullary thyroid carcinomaQ67906753
Immunohistochemical study of medullary thyroid carcinoma: relationship of clinical features to prognostic factors in 36 patientsQ70212686
Relationship of tissue carcinoembryonic antigen and calcitonin to tumor virulence in medullary thyroid carcinoma. An immunohistochemical study in early, localized, and virulent disseminated stages of diseaseQ70367447
Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patientsQ70681913
Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. German Medullary Thyroid Carcinoma Study GroupQ71070755
Germline mutations of the RET proto-oncogene in eight Japanese patients with multiple endocrine neoplasia type 2A (MEN2A)Q72555208
Measurement of serum PDN-21 (Katacalcin) levels by radioimmunoassay in patients with various thyroid diseasesQ72572485
Novel germline RET proto-oncogene mutations associated with medullary thyroid carcinoma (MTC): mutation analysis in Japanese patients with MTCQ73511419
RET proto-oncogene mutation analysis for multiple endocrine neoplasia, type 2Q74689538
Does the syndrome of familial medullary thyroid carcinoma describe a distinct clinical entity?Q77809229
Prognosis of a family with familial medullary thyroid carcinomaQ78178864
Current status of inherited medullary thyroid carcinoma in JapanQ84145294
P433issue2
P921main subjectmultiple endocrine neoplasiaQ1553018
thyroid carcinomaQ18556131
P304page(s)123-131
P577publication date2003-01-01
P1433published inEndocrine PathologyQ15757049
P1476titleMedullary thyroid carcinoma and multiple endocrine neoplasia type 2.
P478volume14